Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.JLL Partners, a private equity investment firm, has completed its acquisition of PharmaNet Development Group, a provider of clinical development services.
Subscribe to our email newsletter
The acquisition was completed on March 30, 2009 through the merger of JLL’s acquisition subsidiary, PDGI Acquisition (purchaser), with and into PharmaNet. As a result of the merger, the outstanding shares of PharmaNet common stock not held by JLL or its affiliates were converted into the right to receive the $5 per share cash merger consideration.
The merger followed the successful completion of the previously announced tender offer by Purchaser and JLL PharmaNet Holdings (parent) for all of the outstanding shares of PharmaNet common stock at a price of $5 per share net to the seller in cash, pursuant to which parent and purchaser acquired approximately 94.8% of the outstanding PharmaNet shares.
Parent and purchaser are affiliates of JLL Partners Fund VI, an investment fund managed by JLL. As a result of the merger and the tender offer, PharmaNet is now wholly owned by JLL through parent.